Akari Therapeutics Plc 8-K

What Happened
Akari Therapeutics, Plc (AKTX) filed an 8-K to report an amendment to its securities purchase agreement and the completion of a combined closing for a previously announced private placement. The company agreed to sell an aggregate of 1,470,588 unregistered American Depository Shares (ADSs) — or prefunded warrants to purchase ADSs — each ADS representing 80,000 ordinary shares. After an initial closing on May 27, 2026, Akari and the investors amended the Purchase Agreement on June 23, 2026 to combine the originally planned second and third closings into a single Combined Closing, which occurred on June 26, 2026, when the company issued the remaining 980,395 ADSs (or prefunded warrants). Delivery of the Series H, I and J warrants related to the offering is contingent on shareholder approval at the company’s annual general meeting on June 30, 2026. The amendment is filed as Exhibit 10.1 to the 8-K.

Key Details

• Total offering size: 1,470,588 ADSs (or prefunded warrants), each ADS representing 80,000 ordinary shares.
• Combined Closing: amendment dated June 23, 2026; remaining 980,395 ADSs issued and sold on June 26, 2026.
• Initial Closing: first tranche closed May 27, 2026; second and third tranches were consolidated into the Combined Closing.
• Series H, I and J warrants: issuance/delivery contingent on shareholder approval at the annual general meeting on June 30, 2026.

Why It Matters
This filing confirms Akari completed the bulk of a previously announced private placement, which brings new capital into the company. Investors should note the potential for future dilution if the ADSs and the related Series warrants are issued or exercised — delivery of the warrants depends on the upcoming shareholder vote (June 30, 2026). The amendment did not change other terms of the Purchase Agreement beyond consolidating the closings, and the amendment document is available as an exhibit to the 8-K for further review.